botensilimab,balstilimab
merck,agenus
[]
intriguing early response data from a phase 1 trial in mss colorectal cancer with botensilimab (novel immune activator ) and balstilimab (antipd1) - phase 3 enrolling now #gi23 
GI medical oncologist, Associate Prof Univ of WI, public health, proud Midwesterner, opinions mine  FCOI: https://t.co/vHScVEaG0b